

1 **NOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: a high-risk**
2 **subgroup with CCL17 (TARC) levels as diagnostic biomarker**

3

4 Emma Kroeze¹, Michelle M Kleisman¹, Lennart A Kester¹, Marijn A Scheijde-Vermeulen¹,
5 Edwin Sonneveld¹, Jessica GC Buijs-Gladdines¹, Melanie M Hagleitner¹, Friederike AG Meyer-
6 Wentrup¹, Margreet A Veening¹, Auke Beishuizen¹, Jules PP Meijerink^{1,†}, Jan LC Loeffen^{1*},
7 Roland P Kuiper^{1,2*}

8

9 ¹*Princess Máxima Center for pediatric oncology, Utrecht, the Netherlands*

10 ²*Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, the*
11 *Netherlands*

12 [†]*Presently working at Acerta-Pharma (AstraZeneca), Oss, the Netherlands*

13 **JLCL and RPK are considered co-last authors*

14

15 **Corresponding author:** Prof. dr. Roland P Kuiper, Princess Maxima Center for Pediatric
16 Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands,
17 r.kuiper@prinsesmaximacentrum.nl

18

19

20 **Abstract**

21 Twenty percent of children with T-cell lymphoblastic lymphoma (T-LBL) will relapse and have
22 an extremely poor outcome. Currently, we can identify a genetically low-risk subgroup in
23 pediatric T-LBL, yet these high-risk patients who need intensified or alternative treatment
24 options remain undetected. Therefore, there is an urgent need to recognize these high-risk
25 T-LBL patients through identification of molecular characteristics and biomarkers. By using
26 RNA sequencing which was performed in 29/49 T-LBL patients who were diagnosed in the

27 Princess Maxima Center for Pediatric Oncology between 2018-2023, we discovered a
28 previously unknown high-risk biological subgroup of children with T-LBL. This subgroup is
29 characterized by *NOTCH1* gene fusions, found in 21% of our T-LBL cohort (6/29). All patients
30 presented with a large mediastinal mass, pleural/pericardial effusions, and absence of blasts
31 in the bone marrow, blood, and central nervous system. Blood CCL17 (C-C Motif Chemokine
32 Ligand 17, TARC) levels were measured at diagnosis in 26/29 patients, and all six patients
33 with *NOTCH1* gene fusions patients exclusively expressed highly elevated blood CCL17 levels,
34 defining a novel and previously not known clinically relevant biomarker for T-cell
35 lymphoblastic lymphoma. Four out of these six patients relapsed during therapy, a fifth
36 developed a therapy related acute myeloid leukemia during maintenance therapy. These
37 data indicate that T-LBL patients with a *NOTCH1* fusion have a high risk of relapse which can
38 be easily identified using a blood CCL17 screening at diagnosis. Further molecular
39 characterization through *NOTCH1* gene fusion analysis offers these patients the opportunity
40 for treatment intensification or new treatment strategies.

41

42 **Introduction**

43 T-cell lymphoblastic lymphoma (T-LBL) is a common pediatric malignancy accounting for
44 approximately 20% of the non-Hodgkin lymphomas during childhood¹. Survival rates of T-
45 LBL are ~80%, but outcome after relapse is dismal, with salvage rates reaching only ~15%^{2,3}.
46 Considering the extremely poor prognosis after relapse and absence of clinically relevant
47 high-risk genetics, there is an urgent need for the identification of molecular risk factors and
48 new prognostic biomarkers in T-LBL, as well as identification of new therapeutic strategies.

49 Pediatric T-LBL is typically characterized by infiltration of blasts in the mediastinum (thymus)
50 and lymph nodes. Approximately half of the cases present with pleural effusion at diagnosis
51 and, by definition, T-LBL patients have less than 25% blasts in the bone marrow (BM)^{4,5}.
52 Based on morphology and immunophenotype, T-LBL is indistinguishable from its leukemic
53 counterpart, T-cell acute lymphoblastic leukemia (T-ALL). T-ALL presents as leukemic disease
54 with $\geq 25\%$ blasts in the BM and presence of blasts in the peripheral blood (PB), but usually
55 with mild mediastinal enlargement. Even though the clinical presentation of T-LBL and T-ALL
56 largely differs, there has been no evidence so far that there are major differences in
57 molecular genetics of T-LBL and T-ALL^{6,7}. Therefore, T-LBL and T-ALL are regarded as
58 different manifestations of the same disease⁸. Pediatric T-ALL has been extensively studied
59 and great advances in treatment protocols have been made, including minimal residual
60 disease (MRD) measurements as a useable stratification strategy. In contrast, molecular
61 genetics underlying T-LBL are still poorly understood and T-LBL patients are currently mainly
62 treated according to ALL-based protocols. Thus far, MRD assessment has not proven to be
63 usable in T-LBL and diagnostic biomarkers to identify high-risk patients are lacking.

64 Diagnostic biomarkers have been successfully introduced in other types of lymphomas. For
65 example, CCL17, also known as blood *thymus and activation-regulated chemokine* (TARC)
66 has proven to be a useful diagnostic biomarker in children with classical Hodgkin
67 lymphoma^{9,10}. It has never been studied whether CCL17 can serve as a biomarker in non-
68 Hodgkin lymphoma and T-LBL in particular. CCL17 is constitutively produced in the thymus,
69 acting as a powerful T-cell chemoattractant. In classical Hodgkin lymphoma patients, CCL17
70 production can be induced by NOTCH1 and CCL17 is highly expressed by the Reed-Sternberg
71 cells, thereby creating a specific supporting tumor microenvironment that recruits T-cells¹⁰.

72 Considering the importance of NOTCH1 and strong preference of malignant T-cells in T-LBL
73 for the thymus, we hypothesize that CCL17 is of importance in the pathophysiology of T-LBL
74 and creating a thymic microenvironment that favors the T-LBL cells.

75 Recent studies show that both T-LBL and T-ALL patients with *NOTCH1* and/or *FBXW7* DNA
76 mutations have a better outcome compared to *NOTCH1* and *FBXW7* wildtype patients^{11,12}.

77 The pathogenic molecular mechanisms of T-LBL patients without *NOTCH1* and/or *FBXW7*
78 mutations remain largely unknown, and this group probably contains both high-risk and low-
79 risk patients. Considering the extremely poor prognosis after relapse, it is essential to
80 identify these high-risk patients. Additionally, there is an urgent need for the identification
81 of new prognostic biomarkers in T-LBL. In this study we present a novel entity of pediatric T-
82 LBL patients characterized by previously unknown *NOTCH1* gene fusions, high risk of relapse,
83 and highly elevated blood CCL17 (TARC) levels

84

85

86 **Methods**

87 ***Patients***

88 We included a complete cohort of all pediatric T-LBL patients (n=49) that were diagnosed in
89 the Princess Máxima Center for Pediatric Oncology between 2018-2024. RNA sequencing
90 data at diagnosis were available for 29/49 patients and at relapse for two additional
91 patients. Clinical information and hematological values at diagnosis were retrieved from
92 patient files. All patients were treated according to the EURO-LB02 protocol³ or its successor,
93 the LBL2018 protocol (NCT04043494). *NOTCH1*/*FBXW7* mutational status was determined

94 for most patients and retrieved from patient files. Pediatric T-ALL patients (n=39) diagnosed
95 between 2019-2022 at the Princess Máxima Center for Pediatric Oncology were included as
96 reference cohort. All sample IDs are completely anonymized. Written informed consent was
97 obtained from all patients and/or their legal guardians included in this study. The study was
98 performed in accordance with the Declaration of Helsinki. The Medical Research Ethical
99 Committee Utrecht declared that the Medical Research Involving Human Subjects Act
100 (WMO) does not apply, and has approved the study (19-140/C).

101

102 ***RNA sequencing analysis***

103 RNA sequencing data was obtained from the in-house diagnostics department in the
104 Princess Máxima Center. The source of biological material is given in **Supplementary Table 1**.
105 Pre-processing of the data was done with standardized and in-house pipelines and
106 guidelines¹³. Fusion detection was performed using STAR fusion¹⁴. In addition, we analyzed
107 the entire T-LBL and T-ALL cohort for exon-specific *NOTCH1* coverage as an indication for
108 fusions, by using DepthOfCoverage of GATK v3.8.0. Whole genome sequencing data (WGS)
109 were also obtained from the in-house diagnostics department and used for validation of
110 genomic breakpoints.

111

112 ***Gene expression analyses***

113 For expression analyses, samples with less than 30 million unique reads were excluded due
114 to lower quality (TLBL042, TLBL046 and TLBL058). For TLBL042, expression data from the
115 relapse were used (TLBL042_R). Gene expression alterations were assessed with log₂

116 transformed gene length normalized read counts (transcript per million mapped reads, TPM)
117 using R v4.4.0. Gene expression variance was determined by calculating standard deviations
118 and the 200 most variable genes were taken in unsupervised clustering using Euclidean
119 distance as a measure of similarity. The R package pheatmap v1.0.12 was implemented for
120 visualizations.

121

122 Differential expression analyses were performed with DESeq2 v1.36.0¹⁵ between NOTCH1-
123 rearranged- and WT cases and between NOTCH1-mutated- and WT cases. Differentially
124 expressed genes were identified after adjustment for false discovery rate (FDR-adjusted p-
125 value ≤ 0.05). Visualisations were generated using R packages EnhancedVolcano v1.12.0 and
126 pheatmap v1.0.12. Subsequently, gene set enrichment analysis (GSEA) was conducted for
127 biological interpretations with clusterProfiler v4.12.0^{16,17}. Genes were ranked according to
128 direction-signed log₁₀-transformed p-values, as determined by DESeq2 v1.36.0, and
129 annotations were provided by implementing the R package AnnotationHub v3.2.2. The
130 ranked gene list was used for Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
131 enrichment analysis. Additionally, z-scores of log₂-transformed TPM values were calculated
132 within the complete T-LBL cohort for genes associated with the NOTCH signaling pathway.
133 ClusterProfiler v4.12.0 and ComplexHeatmap v2.10.0 were implemented for GSEA-result
134 visualizations.

135

136 ***CCL17 (TARC) measurements and immunohistochemistry***

137 CCL17 measurements at diagnosis were performed in serum or plasma of 26 out of the 29
138 patients for whom RNAseq was available. Measurements were performed in triplo by
139 standard enzyme-linked immunosorbent assay (ELISA) using the DuoSet ELISA kit (cat. no.
140 DY364; R&D Systems, Inc.). Immunohistochemistry staining for CCL17 was performed on the
141 BOND-III fully automated staining system (Leica, IL, USA) using CCL17 rabbit polyclonal
142 antibody (ProteinTech group, Chicago IL, USA). Significance of *CCL17* expression between
143 *NOTCH1*-rearranged samples and the rest of the T-LBL RNAseq cohort was determined using
144 DESeq2 v1.36.0.

145

146 **Results**

147 ***Patient characteristics***

148 The pediatric T-LBL patients included in this study (n=49) represented an unselected
149 complete cohort diagnosed in the Princess Máxima Center for Pediatric Oncology between
150 2018-2023. T-LBL diagnoses were based on histopathological classification according to the
151 revised world health organization for hematological malignancies and/or flow cytometry
152 according to the criteria of the European Group for Immunophenotyping of Leukemias^{8,18}.
153 Six out of 49 patients (12%) had a relapse. Informed consent was obtained for 45/49 T-LBL
154 patients and these were therefore used for further analysis. The median age at diagnosis for
155 these 45 patients was ten years, and our cohort contained more males than females (59%),
156 in line with previously described large T-LBL cohorts³. Eighty-eight percent of the patients
157 presented with a large mediastinal mass, which was in 56% of these cases accompanied by
158 pleural effusion. RNAseq was performed for 29/43 patients and their clinical characteristics
159 are described in **Supplementary Table 1**.

160

161 ***Detection of NOTCH1 rearrangements***

162 Transcriptome sequencing was performed at diagnosis from 2019 onwards for all samples
163 with sufficient good quality material available (n=29). This technique allows for the
164 identification and quantification of fusion transcripts and gene expression levels. We
165 identified 12 fusions transcripts in total (12/29, 41%), of which six were *NOTCH1* gene
166 fusions. Fusion partner of *NOTCH1* were the microRNA gene *miR142HG* on chromosome
167 17q22 (TLBL042 and TLBL058), *IKZF2* on chromosome 2q34 (TLBL050) and *TRBJ* on
168 chromosome 7q34 (TLBL033, TLBL049, TLBL050) (**Supplementary Table 2**). The
169 *TRBJ::NOTCH1* fusions were missed by fusion detection algorithms, but were detected
170 because of pronounced expression differences between exons in the 5' and 3' part of the
171 gene (see **Methods**). The fusion transcripts with *miR142HG* and *IKZF2* demonstrated correct
172 splicing to exon 27 or 28 of *NOTCH1* and genomic breakpoints were identified using available
173 whole genome sequencing (WGS) data (**Supplementary Table 2**). *TRBJ::NOTCH1* fusion
174 genes were previously shown to express a truncated, membrane-bound form of *NOTCH1*¹⁹
175 (**Figure 1A**). None of the six samples with a *NOTCH1* gene fusion exhibited mutations in
176 *NOTCH1/FBXW7*, demonstrating the mutual exclusivity of *NOTCH1* mutations and *NOTCH1*-
177 rearrangements. Furthermore, apart from homozygous loss of the *CDKN2A/2B* locus in two
178 cases (TLBL042 and TLBL050), no other driver events were found in these *NOTCH1*-
179 rearranged T-LBLs. *NOTCH1* gene fusions are almost never found in T-ALL, but considering
180 the difficulties in detecting TR-rearranged fusions with conventional pipelines, we also
181 reanalyzed exon-specific *NOTCH1* expression in 39 T-ALL samples that were diagnosed in the
182 Princess Máxima Center for Pediatric Oncology. In line with previous studies^{20,21}, none of the

183 T-ALL samples carried gene fusions involving *NOTCH1*, thus suggesting that the frequent
184 occurrence of these fusions represents an important molecular genetic discriminator
185 between T-LBL and T-ALL.

186

187 ***All NOTCH1 gene fusions result in expression of intracellular NOTCH1***

188 NOTCH1 is a transmembrane protein that is activated through ligand-receptor interaction,
189 which induces a conformational change that results in dissociation of the heterodimerization
190 (HD) subunits. This is followed by exposure of a cleavage site in the C-terminal part of the HD
191 domain, resulting in the release of the intracellular domain of NOTCH1 (NICD). NICD
192 subsequently translocates to the nucleus where it acts as a transcriptional regulator²².

193 To determine whether a truncated C-terminal version of NOTCH1 was indeed expressed in
194 the T-LBL samples with a *NOTCH1*-rearrangement, we performed Western blotting using
195 protein lysates of four *NOTCH1*-rearranged cases and two *NOTCH1* wildtype (*NOTCH1*-WT)
196 cases. All *NOTCH1*-rearrangements lead to expression of NICD. The *IKZF2::NOTCH1*-positive
197 T-LBL (TLBL050) showed expression of an NICD protein co-migrating with the ~130-kDa
198 wildtype NICD, suggesting cleavage of the chimeric protein at the γ -secretase cleavage site
199 (Val1744). In contrast, the *TRBJ::NOTCH1*-positive (TLBL033 and TLBL052) and
200 *miR142HG::NOTCH1*-positive (TLBL042) cases expressed a slightly larger NICD protein, which
201 is in line with translation initiation at methionine residue 1727 (Met1727) encoded in exon
202 28 of *NOTCH1*, as previously reported^{19,23}, and lack of γ -secretase cleavage (**Figure 1B**).

203 To explore the downstream consequences of T-LBL cases with a *NOTCH1* fusion in our T-LBL
204 cohort, we performed unsupervised clustering analysis with the 200 most variable genes in

205 the dataset (**Supplementary Table 3**), which showed that *NOTCH1*-rearranged samples
206 mostly clustered together (**Supplementary Figure 1**). These data indicate that *NOTCH1*-
207 rearranged samples display similar expression profiles among each other. Next, we
208 performed differential expression analysis between *NOTCH1*-rearranged and *NOTCH1*-WT T-
209 LBLs, to determine expression differences. A total of 1,288 genes were found to be
210 significantly differentially expressed, compared to only 101 genes in a comparison between
211 *NOTCH1*-mutated and *NOTCH1*-WT T-LBLs (**Figure 2A,B** and **Supplementary Tables 4 and 5**).
212 These data indicate that *NOTCH1*-mutated and *NOTCH1*-WT cases exhibit comparable
213 expression profiles, whereas *NOTCH1*-rearranged cases differ substantially from the rest of
214 the cohort. Subsequently, we selected the 200 most significantly differentially expressed
215 genes between *NOTCH1*-rearranged and *NOTCH1*-WT T-LBLs for supervised clustering. This
216 analysis revealed that *NOTCH1*-rearranged samples formed a separate cluster, whereas the
217 *NOTCH1* mutated and *NOTCH1*-WT cases are mixed in a second cluster (**Figure 2C**),
218 confirming the unique characteristics of the *NOTCH1* fusion samples.

219 To explore downstream characteristics of *NOTCH1*-rearranged cases, we performed GSEA, to
220 determine enriched KEGG pathways (**Supplementary Figure 2A**). Among others, the NOTCH
221 signaling pathway was significantly activated in *NOTCH1*-rearranged samples compared to
222 *NOTCH1*-WT samples, with an enrichment score of 0.695 (adj. p-value=0.0003 (**Figure 3A,B**)).
223 Enrichment of KEGG pathways was to a lesser extent observed in *NOTCH1*-mutated cases
224 compared to *NOTCH1*-WT samples, including no significant enrichment of the NOTCH
225 signaling pathway (**Supplementary Figure 2B**). These findings suggest that the downstream
226 characteristics and mechanisms of action of the *NOTCH1*-rearranged samples are different
227 from both wildtype and mutant T-LBL samples.

228

229 ***Clinical presentation of patients with NOTCH1 gene fusions***

230 All six patients with *NOTCH1* gene fusions presented with a massively enlarged
231 mediastinum, combined with pleural/pericardial effusion. Moreover, all *NOTCH1* gene
232 fusion-positive patients were bone marrow negative, peripheral blood negative and cerebral
233 spinal fluid negative. These patients therefore had a uniform clinical presentation of disease,
234 although not differentiating between this group and the rest of the T-LBL cohort.
235 Flowcytometry performed at diagnosis revealed positivity for cytoplasmatic CD3 (cyCD3) in
236 all cases, as well as positivity for other T-cell markers. Precursor-marker Terminal
237 Deoxynucleotidyl Transferase (TdT) was expressed in 50% of the *NOTCH1*-rearranged cases,
238 which was lower than expected (~90%)²⁴ (**Supplementary Table 6**). Next, we analyzed blood
239 CCL17 levels, which were highly elevated in all patients with a *NOTCH1* gene fusion (range
240 from 2345 to >10000 pg/ml), compared to 31-638 pg/ml in 16 patients who did not have a
241 *NOTCH1* gene fusion ($p < 0.0001$, t-test) (**Figure 4A**). Follow-up CCL17 levels during first
242 remission were available for 3/6 patients and revealed normalized values (range 57-152
243 pg/ml) (**Figure 4B**). Three of the patients with a clinical relapse (TLBL042, TLBL050 and
244 TLBL058) also showed substantially elevated CCL17 levels at relapse (TLBL042:4613 pg/ml,
245 TLBL050:8654 pg/ml, TLBL058:1662 pg/ml), which could be an indication that CCL17 levels
246 in blood might also increase upon progression of relapse. One patient, whose relapse was
247 discovered with routine imaging, presented with relatively little tumor load and low LDH
248 levels, and did not have increased CCL17 levels (TLBL033) at time of establishing the relapse.
249 CCL17 levels decreased again in second remission (range 69-1331 pg/ml) (**Figure 4C**).
250 Although immunohistochemistry did not reveal positivity of the T-LBL cells for CCL17 (**Figure**

251 **4D**), based on gene expression, *CCL17* was significantly upregulated in the *NOTCH1*-
252 rearranged cases compared to the rest of the T-LBL cohort (FDR-adjusted p-value=0.019).
253 Together, our data strongly indicate that *CCL17* can serve as a high-risk biomarker at
254 diagnosis.

255

256 ***NOTCH1* gene fusions as poor prognostic marker in T-LBL**

257 Finally, we aimed to determine the prognostic relevance of *NOTCH1* gene fusions in T-LBL.
258 We found that five out of six *NOTCH1* fusion-positive patients had an event. Four patients
259 had a relapse during therapy (TLBL033, TLBL042, TLBL050, TLBL058), one of them is still
260 under treatment, the other three could not be rescued. Additionally, one patient had a
261 therapy-related acute myeloid leukemia (t-AML) during maintenance therapy of T-LBL
262 (TLBL049), leaving just one *NOTCH1*-fusion positive patient without an event. The t-AML
263 carried the typical *KMT2A::MLL3* fusion. This patient was rescued with AML induction
264 chemotherapy followed by allogeneic stem cell transplantation. The sixth *NOTCH1*-fusion
265 positive patient did not have an event, yet this patient is still under maintenance treatment.
266 In the rest of the cohort, one event occurred, which was death due to pancreatitis
267 complicated by a septic shock (**Figure 5**). Our data therefore shows a significant difference in
268 cumulative incidence of events between the *NOTCH1*-fusion group and the rest of the
269 cohort (p<0.001)

270 The unselected 5-year T-LBL cohort (n=49) contained six patients who relapsed, of whom
271 four had a *NOTCH1* gene fusion. For the other two patients, only RNAseq data at relapse was
272 available, revealing a *DDX3X::MLL10* fusion and a *JAKMIP2::PDGFRB* fusion at relapse,
273 respectively, established high-risk ALL aberrations^{20,25}. Thus, *NOTCH1*-rearranged T-LBL

274 caused the majority of relapses in our cohort, suggesting that they cause an aggressive T-LBL
275 phenotype, with a significantly higher cumulative incidence of relapse ($p < 0.001$, Gray's test)
276 compared to the *NOTCH1*-fusion negative patients.

277

278 **Discussion**

279 To date, mainly clinically applicable low-risk genetics have been described for T-LBL. This
280 implicates that molecular genetic high-risk patients who need intensified or alternative
281 treatment strategies are undetected. Moreover, patients with unknown low-risk molecular
282 genetic profiles could also be overtreated with current treatment strategies.

283 We discovered a biological high-risk subgroup of T-LBL, characterized by *NOTCH1* gene
284 fusions. This subgroup represents 21% (6/29 patients) of our T-LBL cohort. All patients had a
285 similar although not unique presentation of disease predominantly consisting of a large
286 mediastinal mass, pleural/pericardial effusion and highly elevated CCL17 (TARC) levels in
287 blood. Moreover, four out of six patients with a *NOTCH1* gene fusion had a relapse and did
288 not survive, indicating that *NOTCH1* fusions lead to an aggressive T-LBL phenotype. Fifty
289 percent of the *NOTCH1*-rearranged cases exhibited expression of TdT, which is lower than
290 the expected 90%. It has been described before that the TdT-negative subset often
291 represent diagnostically challenging cases with phenotypic features that are consistent with
292 a late cortical subtype, coinciding with what we found in our cohort²⁴.

293 The presence and frequency of *NOTCH1* gene fusions can currently be regarded as a major
294 molecular genetic difference between T-LBL and T-ALL, since fusions involving *NOTCH1* are
295 only extremely rarely described in T-ALL ($< 0.1\%$)^{21,26-31}. The uniform absence of BM and PB

296 involvement in T-LBL patients with a *NOTCH1* gene fusion coincides with the fact that these
297 rearrangements have almost never been detected in T-ALL. *NOTCH1* gene fusions have been
298 described in T-LBL before²⁸, but given the small number of samples in these studies, as well
299 as difficulties in detecting TR-rearranged fusions with conventional pipelines, these fusions
300 might have been missed explaining the lower contribution of *NOTCH1* gene fusions in these
301 studies.

302 *NOTCH1* gene fusions appear to have more impact on T-LBL cells compared to *NOTCH1*
303 mutations, with more and larger changes in the downstream gene expression and *NOTCH1*
304 activity, independent of the type of *NOTCH1*-fusion. Furthermore, whereas patients with
305 *NOTCH1* and/or *FBXW7* mutations are considered low risk and have a better outcome
306 compared to *NOTCH1* and/or *FBXW7* WT patients^{11,12}, we demonstrate that the outcome of
307 these recurrent *NOTCH1*-rearranged T-LBLs is poor. It has recently been described that
308 *NOTCH1* intronic single nucleotide variants (SNVs) and *NOTCH1* intragenic losses were also
309 associated with an inferior event-free and overall survival³¹, further substantiating that
310 distinct genetic aberrations in *NOTCH1* have a different impact on outcome. The T-LBL
311 patients with high-risk *NOTCH1* aberrations will probably need intensified or alternative
312 treatment strategies. A second consequence of our findings may be that when *NOTCH1* gene
313 fusions are recognized as a separate high-risk group, the survival characteristics of the
314 remaining group of T-LBL patients with unknown molecular genetics improves and may
315 benefit from less intensified treatment.

316 The highly elevated blood CCL17 levels were exclusively observed in all T-LBL patients with a
317 *NOTCH1*-rearrangement, even though almost all T-LBL patients had an enlarged
318 mediastinum. Elevated CCL17 levels may therefore serve as an important biomarker to

319 assist in the diagnosis of this high-risk group at diagnosis. Moreover, there might be a
320 possibility that CCL17 levels could be used during follow-up as well, but these findings need
321 to be validated in larger cohorts. In classical Hodgkin lymphoma, it has been suggested that
322 inhibiting CCL17, produced by the Reed-Sternberg cells, may have therapeutic consequences
323 in classical Hodgkin lymphoma as inhibiting CCL17 can decrease the recruitment of T-cells,
324 thereby affecting the supporting microenvironment³². Our data suggest that CCL17 protein
325 levels in the tumor cells of *NOTCH1*-rearranged tumor cells is only slightly increased and
326 rapidly secreted based on immunohistochemistry, while *CLL17* gene expression and blood
327 levels are highly increased. This likely points towards active crosstalk between the tumor
328 cells and the microenvironment³³. It is therefore intriguing to further explore whether
329 *NOTCH1*-rearranged T-LBLs are dependent on CCL17 expression and whether this would
330 provide opportunities for targeted treatment in a potentially high-risk subgroup of T-LBL.
331 Measuring blood CCL17 levels could also serve as an easily applicable technique to identify
332 high-risk T-LBL patients in low- and middle-income countries with restricted access to next
333 generation sequencing techniques.

334 In conclusion, we discovered that, in contrast to T-ALL, *NOTCH1* gene fusions are common in
335 T-LBL and represent a high-risk subtype with an easily applicable biomarker. The discovery of
336 this clinically relevant high-risk T-LBL subgroup offers opportunities to develop intensified
337 and targeted treatment strategies for this subgroup and decrease overtreatment in the
338 remaining group of T-LBL patients.

339

340 **Data sharing agreement**

341 Exome and transcriptome data will be submitted to the European Genome-Phenome
342 Archive (EGA) for controlled-access data sharing (EGAS00001007703).

343

344 **Author contributions**

345 RK, JLCL, AB designed the study. EK wrote the manuscript and analyzed the data. MMK and
346 LAK performed the bioinformatic analyses. JGCB performed the wet lab analyses. ES
347 provided laboratory supervision. MSV performed the histological analyses. MMH, FAGM,
348 MAV were involved in data curation. JPPM acquired the funding.

349

350 **Declaration of interests**

351 None of the authors declare a conflict of interest.

352

353 **References**

- 354 1. Minard-Colin V, Brugieres L, Reiter A, et al. Non-Hodgkin Lymphoma in Children and
355 Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges
356 Ahead. *J Clin Oncol* 2015;33(27):2963-74. DOI: 10.1200/JCO.2014.59.5827.
- 357 2. Burkhardt B, Reiter A, Landmann E, et al. Poor outcome for children and adolescents with
358 progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-
359 frankfurt-muenster group. *J Clin Oncol* 2009;27(20):3363-9. DOI: 10.1200/JCO.2008.19.3367.
- 360 3. Landmann E, Burkhardt B, Zimmermann M, et al. Results and conclusions of the European
361 Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma.
362 *Haematologica* 2017;102(12):2086-2096. DOI: 10.3324/haematol.2015.139162.

- 363 4. Swerdlow SH, Campo E, Lee Harris N, et al. WHO Classification of Tumours of Haematopoietic
364 and Lymphoid Tissues (Revised 4th edition). World Health Organization Classification of
365 Tumours. Lyon, France: International Agency for Research on Cancer (IARC); 2017.
- 366 5. Rosolen A, Perkins SL, Pinkerton CR, et al. Revised International Pediatric Non-Hodgkin
367 Lymphoma Staging System. *J Clin Oncol* 2015;33(18):2112-8. DOI:
368 10.1200/JCO.2014.59.7203.
- 369 6. Khanam T, Sandmann S, Seggewiss J, et al. Integrative genomic analysis of pediatric T- cell
370 lymphoblastic lymphoma reveals candidates of clinical significance. *Blood* 2020. DOI:
371 10.1182/blood.2020005381.
- 372 7. Bontoux C, Simonin M, Garnier N, et al. Oncogenetic landscape of T-cell lymphoblastic
373 lymphomas compared to T-cell acute lymphoblastic leukemia. *Mod Pathol* 2022;35(9):1227-
374 1235. DOI: 10.1038/s41379-022-01085-9.
- 375 8. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health
376 Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. *Leukemia*
377 2022;36(7):1720-1748. DOI: 10.1038/s41375-022-01620-2.
- 378 9. Zijtregtop EAM, Diez C, Zwaan CM, Veening MA, Beishuizen A, Meyer-Wentrup FAG. Thymus
379 and activation-regulated chemokine (TARC) as treatment response marker for paediatric
380 Hodgkin lymphoma: A pilot study. *Br J Haematol* 2023;200(1):70-78. DOI:
381 10.1111/bjh.18473.
- 382 10. Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1
383 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell
384 lymphoma. *Blood* 2002;99(9):3398-403. DOI: 10.1182/blood.v99.9.3398.
- 385 11. Bonn BR, Rohde M, Zimmermann M, et al. Incidence and prognostic relevance of genetic
386 variations in T-cell lymphoblastic lymphoma in childhood and adolescence. *Blood*
387 2013;121(16):3153-60. DOI: 10.1182/blood-2012-12-474148.

- 388 12. Callens C, Baleyrier F, Lengline E, et al. Clinical impact of NOTCH1 and/or FBXW7 mutations,
389 FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. *J Clin Oncol*
390 2012;30(16):1966-73. DOI: 10.1200/JCO.2011.39.7661.
- 391 13. Hehir-Kwa JY, Koudijs MJ, Verwiel ETP, et al. Improved Gene Fusion Detection in Childhood
392 Cancer Diagnostics Using RNA Sequencing. *JCO Precis Oncol* 2022;6:e2000504. DOI:
393 10.1200/PO.20.00504.
- 394 14. Haas BJ, Dobin A, Stransky N, et al. STAR-Fusion: Fast and Accurate Fusion Transcript
395 Detection from RNA-Seq. *BioRxiv* 2017.
- 396 15. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-
397 seq data with DESeq2. *Genome Biol* 2014;15(12):550. DOI: 10.1186/s13059-014-0550-8.
- 398 16. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes
399 among gene clusters. *OMICS* 2012;16(5):284-7. DOI: 10.1089/omi.2011.0118.
- 400 17. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-
401 based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A*
402 2005;102(43):15545-50. DOI: 10.1073/pnas.0506580102.
- 403 18. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute
404 leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).
405 *Leukemia* 1995;9(10):1783-6. (<https://www.ncbi.nlm.nih.gov/pubmed/7564526>).
- 406 19. Palomero T, Barnes KC, Real PJ, et al. CUTLL1, a novel human T-cell lymphoma cell line with
407 t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase
408 inhibitors. *Leukemia* 2006;20(7):1279-87. DOI: 10.1038/sj.leu.2404258.
- 409 20. Steimle T, Dourthe ME, Alcantara M, et al. Clinico-biological features of T-cell acute
410 lymphoblastic leukemia with fusion proteins. *Blood Cancer J* 2022;12(1):14. DOI:
411 10.1038/s41408-022-00613-9.
- 412 21. Brady SW, Roberts KG, Gu Z, et al. The genomic landscape of pediatric acute lymphoblastic
413 leukemia. *Nat Genet* 2022;54(9):1376-1389. DOI: 10.1038/s41588-022-01159-z.

- 414 22. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation
415 mechanism. *Cell* 2009;137(2):216-33. DOI: 10.1016/j.cell.2009.03.045.
- 416 23. Ashworth TD, Pear WS, Chiang MY, et al. Deletion-based mechanisms of Notch1 activation in
417 T-ALL: key roles for RAG recombinase and a conserved internal translational start site in
418 Notch1. *Blood* 2010;116(25):5455-64. DOI: 10.1182/blood-2010-05-286328.
- 419 24. Patel JL, Smith LM, Anderson J, et al. The immunophenotype of T-lymphoblastic lymphoma
420 in children and adolescents: a Children's Oncology Group report. *Br J Haematol*
421 2012;159(4):454-61. DOI: 10.1111/bjh.12042.
- 422 25. Tasian SK, Loh ML, Hunger SP. Philadelphia chromosome-like acute lymphoblastic leukemia.
423 *Blood* 2017;130(19):2064-2072. DOI: 10.1182/blood-2017-06-743252.
- 424 26. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the *Drosophila* notch gene, is
425 broken by chromosomal translocations in T lymphoblastic neoplasms. *Cell* 1991;66(4):649-
426 61. DOI: 10.1016/0092-8674(91)90111-b.
- 427 27. Speleman F, Cauwelier B, Dastugue N, et al. A new recurrent inversion, inv(7)(p15q34), leads
428 to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic
429 leukemias. *Leukemia* 2005;19(3):358-66. DOI: 10.1038/sj.leu.2403657.
- 430 28. Salmeron-Villalobos J, Ramis-Zaldivar JE, Balague O, et al. Diverse mutations and structural
431 variations contribute to Notch signaling deregulation in paediatric T-cell lymphoblastic
432 lymphoma. *Pediatr Blood Cancer* 2022;69(11):e29926. DOI: 10.1002/pbc.29926.
- 433 29. Yamamoto K, Nakamachi Y, Yakushijin K, et al. A novel TRB@/NOTCH1 fusion gene in T-cell
434 lymphoblastic lymphoma with t(7;9)(q34;q34). *Eur J Haematol* 2013;90(1):68-75. DOI:
435 10.1111/ejh.12019.
- 436 30. Liu Y, Easton J, Shao Y, et al. The genomic landscape of pediatric and young adult T-lineage
437 acute lymphoblastic leukemia. *Nat Genet* 2017;49(8):1211-1218. DOI: 10.1038/ng.3909.
- 438 31. Mullighan C, Pölönen P, Giacomo DD, et al. [preprint] The genomic basis of childhood T-
439 lineage acute lymphoblastic leukemia. *Research Square*.

- 440 32. Zijtregtop EAM, van der Strate I, Beishuizen A, et al. Biology and Clinical Applicability of
441 Plasma Thymus and Activation-Regulated Chemokine (TARC) in Classical Hodgkin Lymphoma.
442 *Cancers (Basel)* 2021;13(4). DOI: 10.3390/cancers13040884.
- 443 33. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. *Blood*
444 2002;99(12):4283-97. DOI: 10.1182/blood-2002-01-0099.

445

446 **Figure legends**

447 **Figure 1: NOTCH1-rearrangements in T-LBL.** A) Schematic representation of three different
448 *NOTCH1* fusions with different fusion partners. The in-frame *IKZF2::NOTCH1* fusion
449 generates a chimeric protein in which the N-terminal DNA binding domain of IKZF2 is fused
450 to the C-terminal intracellular domains of NOTCH1. Fusions transcripts with *miR142HG* and
451 *TRBJ* use an alternative translation start site in exon 28 (Met1727). B) Western blot analysis
452 using Val1744 antibody (Cell Signaling Inc.) shows that *miR142HG::NOTCH1* and the
453 *TRBJ::NOTCH1* fusions lead to a larger NICD protein, likely representing uncleaved NICD with
454 translation initiation at Met1727. Simultaneous Beta-actin staining was performed for
455 loading comparisons.

456

457 **Figure 2: Gene expression differences in NOTCH1-rearranged, mutated and wildtype T-LBL.**
458 A+B) Volcano plots showing differentially expressed genes between *NOTCH1*-rearranged and
459 *NOTCH1*-WT samples (n=1,288; panel A) and between *NOTCH1*-mutated and *NOTCH1* WT
460 samples (n=101; panel B) C) Expression analysis of the 200 most significantly up- and
461 downregulated genes (from a total of 1,288 genes) in *NOTCH1*-rearranged compared to
462 *NOTCH1*-WT samples, revealed that *NOTCH1*-rearranged samples cluster separately from

463 NOTCH1 WT and NOTCH1-mutated samples using Euclidean distance as a measure of
464 similarity. The relapse sample of TLBL042 was used because of better quality. Range of 0-10
465 showing the log₂-transformed TPM values. Significance was determined using false
466 discovery rate (FDR)-adjusted p-values.

467

468 **Figure 3: GSEA results of the NOTCH signaling pathway.** A) Enrichment plot for the NOTCH
469 signaling pathway in the *NOTCH1*-rearranged versus WT samples, showing the profile of the
470 running enrichment score and positions of genes associated with this pathway on the rank-
471 ordered gene list. B) Z-scores of log₂-transformed TPM values of genes associated with the
472 NOTCH signaling pathway within the complete T-LBL cohort. Mean z-scores are depicted for
473 *NOTCH1*-rearranged, *NOTCH1*-mutated and WT samples. Genes are ranked based on their
474 position in the rank-ordered gene list used for GSEA between *NOTCH1*-rearranged and WT
475 samples.

476

477 **Figure 4: CCL17 (TARC) in *NOTCH1*-rearranged patients.** A) CCL17 levels in pg/ml per
478 patient, showing highly elevated CCL17 in blood of *NOTCH1*-rearranged T-LBL patients but
479 none of the other patients. 10000 pg/ml is the maximum measurable CCL17 level with used
480 assay. Orange line in figure A, B and C represents maximum normal CCL17 level (1300 pg/ml)
481 based on what has been described in Hodgkin lymphoma⁹. Patients that had a relapse are
482 indicated with an asterisk. Patient TLBL049 developed a therapy-related AML (double
483 asterisk). B) For three *NOTCH1*-rearranged patients, blood CCL17 levels could be determined
484 for a time point of remission after diagnosis, revealing normalized CCL17 levels in all three
485 cases. C) For four *NOTCH1*-rearranged patients blood CCL17 levels were determined at time




486 point of relapse and remission after relapse (second remission), revealing increased levels in
487 three relapses that again normalized in second remission. D) Staining for TARC using anti-
488 CCL17 antibody for four *NOTCH1*-rearranged patients showing that T-LBL cells do not
489 express high levels of CCL17 based on immunohistochemistry.

490

491 **Figure 5: Cumulative incidence plot of events reveals a significant higher cumulative**
492 **incidence of relapse in *NOTCH1*-rearranged cases compared to the rest of the T-LBL cohort**
493 **(3 years) ($p < 0.001$).** The p-value is estimated using Gray's test. Four relapses occurred in the
494 *NOTCH1*-rearranged cohort. No relapses occurred in the cohort. In both cohorts, one other
495 event occurred, which was a therapy related-AML in the *NOTCH1*-rearranged cohort and
496 death due to pancreatitis complicated by a septic shock in the other cohort.

497


A



NOTCH1 domains




B




A

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.31.24301517>; this version posted May 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




B




● NS ● Log2 FC ● p-value ● p-value and log2 FC


C




A




B




A





B




C



D





***NOTCH1*-fusion**

| | | | | | | | |
|---------|---|---|---|---|---|---|---|
| At Risk | 6 | 4 | 3 | 2 | 1 | 1 | 1 |
| Events | 0 | 2 | 4 | 4 | 4 | 4 | 4 |

Other

| | | | | | | | |
|---------|----|----|----|----|----|---|---|
| At Risk | 23 | 22 | 21 | 15 | 12 | 5 | 3 |
| Events | 0 | 0 | 0 | 0 | 0 | 0 | 0 |